Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) provides an ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Encoded’s layoffs will mostly affect its technology and early-stage research and development functions. The move is expected ...

Neumora will host a conference call and live webcast at 8:00 a.m. ET on Monday, March 3, 2025 to report its fourth quarter and full year 2024 financial results and provide a business update.

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

2 new ACLF clinical trials expected to initiate in 1Q25 3 clinical ... Evidence Supporting ACLF Pipeline Strategic Development New trials, set to launch, build on key 2024 findings from complementary ...